Moreover, perturbation of PPARγ signaling with novel PPARγ agonists and antagonists is gaining attention as a strategy for the treatment of several cancers, including breast cancer (Ahmed et al., 2007; Chandra et al., 2017). This evidence concerns the gene PPARG and breast carcinoma.